• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Oncocyte Appoints Andrea James as Chief Financial Officer

    6/17/24 4:05:00 PM ET
    $AXON
    $OCX
    Ordnance And Accessories
    Industrials
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $AXON alert in real time by email

    IRVINE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer.

    "We are thrilled to welcome Andrea as we approach the inflection point of commercial launch," Oncocyte CEO Josh Riggs said. "She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building relationships with high quality institutional investors. Andrea is therefore an ideal CFO business partner to myself, the Board of Directors and the Oncocyte team.

    "We expect 2024 and 2025 to be transformative years for Oncocyte. We have begun to establish our diagnostic tests as the research tool of choice for the transplant community together with our co-marketing partner Bio-Rad Laboratories. Separately, we also see the opportunity to unlock high-value clinical diagnostic opportunities in the oncology space and add to our commercialization partnerships. We eagerly anticipate Andrea's valuable insights as we continue to drive value creation for Oncocyte's shareholders."

    Prior to joining Oncocyte, Ms. James served as Chief Communications Officer and head of investor relations at Axon Enterprise, Inc. (NASDAQ:AXON). She joined Axon's finance team in 2017 to build the company's investor relations function and played an integral role through the company's growth from $1 billion in market capitalization to a company valued at more than $20 billion. She led Axon's repositioning as a top-tier technology company with the investment community and established Axon's corporate strategy function, overseeing capital stewardship, mergers and acquisitions, strategic partnerships and investments. Her work was instrumental in supporting more than $550 million in equity capital offerings.

    Ms. James worked in a strategic investor relations role for Tesla, Inc. in 2016 and 2017. From 2009 to 2016 she worked as a sell-side analyst for Dougherty & Company (now Colliers Securities), becoming a vice president and senior research analyst. At Dougherty, she researched emerging technologies on behalf of institutional investors. Previously, she was a reporter at publications including Bloomberg News and the Seattle Post-Intelligencer covering a range of business and financial beats.

    "Oncocyte is a disruptive innovator in the field of molecular diagnostics that is on track for category leadership. The company enjoys a top-notch management team with extensive experience in this space," Ms. James said. "I am delighted to join and look forward to helping to scale the company into a much larger, highly profitable enterprise over time, while also ensuring that the capital markets understand our exciting runway and global market opportunity."

    "I also want to commend James Liu, who has served as Oncocyte's controller and principal accounting officer and who will continue to serve as an important leader within our finance team," James added.

    Ms. James holds a Bachelor of Science, summa cum laude, in Computer Information Systems from American University. She also holds a Master of Science in Journalism from Northwestern University, graduating with Kappa Tau Alpha honors. While at Dougherty, her Financial Industry Regulatory Authority (FINRA) licenses included the Series 7, 86, 87 and 63.

    About Oncocyte

    Oncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:

    VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/

    VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/

    GraftAssure™ - https://oncocyte.com/graftassure/

    DetermaIO™ - https://oncocyte.com/determa-io/

    DetermaCNI™ - https://oncocyte.com/determa-cni/

    VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

    Forward-Looking Statements

    Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates," "may," and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, Oncocyte's ongoing commercialization efforts and Ms. James' expected contributions to the Company, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors" and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    CONTACT:

    Jeff Ramson

    PCG Advisory

    (646) 863-6893

    [email protected]



    Primary Logo

    Get the next $AXON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXON
    $OCX

    CompanyDatePrice TargetRatingAnalyst
    Oncocyte Corporation
    $OCX
    3/28/2025$5.00Buy
    Lake Street
    Axon Enterprise Inc.
    $AXON
    2/20/2025$625.00Buy → Hold
    Craig Hallum
    Axon Enterprise Inc.
    $AXON
    2/19/2025Buy → Neutral
    Northcoast
    Axon Enterprise Inc.
    $AXON
    1/8/2025$700.00Buy
    TD Cowen
    Axon Enterprise Inc.
    $AXON
    12/3/2024$500.00 → $700.00Equal-Weight → Overweight
    Morgan Stanley
    Axon Enterprise Inc.
    $AXON
    9/12/2024$375.00 → $430.00Mkt Outperform
    JMP Securities
    Axon Enterprise Inc.
    $AXON
    7/17/2024$380.00Buy
    BofA Securities
    Axon Enterprise Inc.
    $AXON
    7/17/2024$385.00Buy
    Jefferies
    More analyst ratings

    $AXON
    $OCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      12/9/24 5:30:06 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Oncocyte Corporation

      SC 13G - Oncocyte Corp (0001642380) (Subject)

      11/14/24 1:26:16 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      10/24/24 12:13:28 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AXON
    $OCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 7:00:32 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 5:00:15 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Broadwood Partners, L.P. bought $10,589,675 worth of shares (5,165,695 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/10/25 8:43:04 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AXON
    $OCX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Oncocyte Corporation

      SCHEDULE 13G/A - Oncocyte Corp (0001642380) (Subject)

      5/9/25 4:06:55 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Axon Enterprise Inc.

      10-Q - AXON ENTERPRISE, INC. (0001069183) (Filer)

      5/7/25 4:41:36 PM ET
      $AXON
      Ordnance And Accessories
      Industrials
    • Amendment: SEC Form 10-K/A filed by Axon Enterprise Inc.

      10-K/A - AXON ENTERPRISE, INC. (0001069183) (Filer)

      5/7/25 4:38:11 PM ET
      $AXON
      Ordnance And Accessories
      Industrials

    $AXON
    $OCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oncocyte to Release First Quarter 2025 Results on May 12, 2025

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

      5/7/25 4:10:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Axon reports Q1 2025 revenue of $604 million, up 31% year over year

      SCOTTSDALE, Ariz., May 7, 2025 /PRNewswire/ -- Software & Services revenue grows 39% to $263 millionAnnual recurring revenue grows 34% to $1.1 billionNet income of $88 million supports non-GAAP net income of $115 million and Adjusted EBITDA of $155 millionRaises full year revenue outlook to a range of $2.60 billion to $2.70 billion, up from $2.55 billion to $2.65 billion Fellow shareholders, Axon delivered a strong start to 2025, achieving record quarterly revenue while maintaining healthy margins and reinforcing our foundation for long-term growth through continued product in

      5/7/25 4:01:00 PM ET
      $AXON
      Ordnance And Accessories
      Industrials
    • Oncocyte Provides Positive Update on Clinical Trial Progress

      Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc

      4/30/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AXON
    $OCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Smith Patrick W sold $5,409,861 worth of shares (10,000 units at $540.99), decreasing direct ownership by 0.33% to 3,063,982 units (SEC Form 4)

      4 - AXON ENTERPRISE, INC. (0001069183) (Issuer)

      4/23/25 4:42:07 PM ET
      $AXON
      Ordnance And Accessories
      Industrials
    • New insider Mak Jennifer H claimed ownership of 17,465 shares (SEC Form 3)

      3 - AXON ENTERPRISE, INC. (0001069183) (Issuer)

      4/4/25 4:23:43 PM ET
      $AXON
      Ordnance And Accessories
      Industrials
    • SEC Form 4 filed by Chief Financial Officer James Andrea S.

      4 - Oncocyte Corp (0001642380) (Issuer)

      3/28/25 4:05:18 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AXON
    $OCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on OncoCyte with a new price target

      Lake Street initiated coverage of OncoCyte with a rating of Buy and set a new price target of $5.00

      3/28/25 8:35:58 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Axon downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Axon from Buy to Hold and set a new price target of $625.00

      2/20/25 8:17:48 AM ET
      $AXON
      Ordnance And Accessories
      Industrials
    • Axon downgraded by Northcoast

      Northcoast downgraded Axon from Buy to Neutral

      2/19/25 8:45:33 AM ET
      $AXON
      Ordnance And Accessories
      Industrials

    $AXON
    $OCX
    Financials

    Live finance-specific insights

    See more

    $AXON
    $OCX
    Leadership Updates

    Live Leadership Updates

    See more
    • Oncocyte to Release First Quarter 2025 Results on May 12, 2025

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

      5/7/25 4:10:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Axon reports Q1 2025 revenue of $604 million, up 31% year over year

      SCOTTSDALE, Ariz., May 7, 2025 /PRNewswire/ -- Software & Services revenue grows 39% to $263 millionAnnual recurring revenue grows 34% to $1.1 billionNet income of $88 million supports non-GAAP net income of $115 million and Adjusted EBITDA of $155 millionRaises full year revenue outlook to a range of $2.60 billion to $2.70 billion, up from $2.55 billion to $2.65 billion Fellow shareholders, Axon delivered a strong start to 2025, achieving record quarterly revenue while maintaining healthy margins and reinforcing our foundation for long-term growth through continued product in

      5/7/25 4:01:00 PM ET
      $AXON
      Ordnance And Accessories
      Industrials
    • Oncocyte Provides Positive Update on Clinical Trial Progress

      Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its clinical trial, which is a major step required to obtain regulatory authorization to deliver an organ transplant rejection monitoring test kit to the market. Oncoc

      4/30/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

      Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory and reimbursement supportWill assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer. In this part-time role, he will support a range of strategic and clinical goals for Oncocyte. Dr. Billings is a recognized pioneer in genomics and precision medicine with over 40 years of experience spanning academia, government,

      1/8/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

      NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte's (NASDAQ:OCX) appointment of leading finance executive, Andrea James, as Chief Financial Officer. This strategic move comes at a pivotal time as Oncocyte prepares for significant commercial and regulatory milestones expected in 2024 and 2025. Under the leadership of CEO Josh Riggs, Oncocyte is poised for a transformative period with its upcoming commercial launches. The company's flagship products, the VitaGraft™ Kidney diagnostic test and its research use only (RUO) GraftAssure

      6/24/24 12:41:19 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care